Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 6/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1649294 | 0.92 | PLA2G2C (0.44) | PLA2G2CSIRT6SIRT1PLA2G2AMAPK1 | |
| SCHEMBL4323327 | 0.92 | PLA2G2C (0.44) | PLA2G2CSIRT6SIRT1PLA2G2AMAPK1 | |
| SCHEMBL8526417 | 0.85 | MAPT (0.48) | PLA2G2CMAPTGPR84FFAR1ZDHHC7 | |
| SCHEMBL56437 | 0.84 | HDAC7 (0.35) | PLA2G2CSIRT6SIRT1MAPTPLA2G2A | |
| SCHEMBL15284017 | 0.84 | PLA2G2C (0.44) | PLA2G2CSIRT6SIRT1MAPTPLA2G2A | |
| SCHEMBL15284019 | 0.84 | PLA2G2C (0.44) | PLA2G2CSIRT6SIRT1MAPTPLA2G2A | |
| SCHEMBL1328597 | 0.81 | SIRT6 (0.44) | SIRT6SIRT1CA2 | |
| SCHEMBL18425829 | 0.81 | MAPT (0.41) | PLA2G2CMAPTGPR84FFAR1ZDHHC7 | |
| SCHEMBL10935678 | 0.79 | TRPV1 (0.33) | MAPT | |
| SCHEMBL8597199 | 0.79 | SPHK1 (0.38) | MAPTGPR84FFAR1ZDHHC7LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210308090-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210275491-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2021-09-09 | — | — | US | disclosed |
| US-11033525-B2 | Fap-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-10828346-B2 | Compositions and methods for modulating stem cells and uses thereof | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2020-11-10 | — | — | US | disclosed |
| US-20200297745-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | BACH BIOSCIENCES, LLC | 2020-09-24 | — | — | US | disclosed |
| WO-2004113513-A2 | METHODS AND COMPOSITIONS FOR MODULATING STEM CELL GROWTH AND DIFFERENTIATION | OTTAWA HEALTH RESEARCH INSTITUTE (CA) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004111078-A2 | COMPOUNDS THAT MODULATE THE GLUCAGON RESPONSE AND USES THEREOF | THERATECHNOLOGIES INC. (CA) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004108756-A2 | SARS CORONAVIRUS PEPTIDES AND USES THEREOF | PEGASUS PHARMACEUTICALS GROUP INC. (CA) | 2004-12-16 | — | — | WO | disclosed |
| US-20040235749-A1 | G-protein coupled receptor antagonists | HOPITAL SAINTE-JUSTINE (CA) | 2004-11-25 | — | — | US | disclosed |
| WO-2004046317-A2 | PRODUCTS AND PROCESSES FOR MODULATING PEPTIDE-PEPTIDE BINDING DOMAIN INTERACTIONS | MASSACHUSETTS INSTITUE OF TECHNOLOGY (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20030157644-A1 | Peptides and other small molecules derived from regions of interacting proteins and uses thereof | MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK | 2003-08-21 | — | — | US | disclosed |
| US-6555522-B1 | Derived from G beta subunit of heterotrimeric GTP (glutamyltransferase) binding proteins; for modulating adenylyl cyclase and phospholipase C- beta 2 activities | MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY OF NEW YORK | 2003-04-29 | — | — | US | disclosed |
| US-6126939-A | GLU-ARG; INHIBITS MACROPHAGE ACTIVITY AND HAS MACROPHAGE MIGRATION AND/OR MACROPHAGE PHAGOCYTIC INHIBITORY ACTIVITY | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2000-10-03 | — | — | US | disclosed |
| EP-0927191-A2 | ANTI-INFLAMMATORY PEPTIDES AND USES THEREOF | YEDA RESEARCH & DEVELOPMENT COMPANY, LTD. (IL) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998009985-A2 | ANTI-INFLAMMATORY PEPTIDES AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | PLA2G2C 1231/4885SIRT6 1445/4885SIRT1 1577/4885 |
| US-11033525-B2 | Fap-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | PLA2G2C 828/4885SIRT6 1693/4885SIRT1 2311/4885 |
| US-20210275491-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | PLA2G2C 828/4885SIRT6 1693/4885SIRT1 2311/4885 |
| US-20210308090-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | PLA2G2C 828/4885SIRT6 1693/4885SIRT1 2311/4885 |
| US-20200297745-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | FAP, FIBP, GOT1 | PLA2G2C 1231/4885SIRT6 1445/4885SIRT1 1577/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | PLA2G2C 828/4885SIRT6 1693/4885SIRT1 2311/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | PLA2G2C 1203/4885SIRT6 1410/4885SIRT1 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.